U.S. Markets closed

Kronos Bio, Inc. (KRON)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.72-0.01 (-0.04%)
At close: 4:00PM EDT

25.72 0.00 (0.00%)
After hours: 5:03PM EDT

Kronos Bio, Inc.

1300 South El Camino Real
Suite 300
San Mateo, CA 94402
United States
650 781 5200
http://kronosbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees63

Key Executives

NameTitlePayExercisedYear Born
Dr. Norbert W. BischofbergerPres, CEO & Director280kN/A1956
Mr. Jorge F. DiMartino M.D., Ph.D.Chief Medical Officer & Exec. VP of Clinical Devel.398.27kN/A1963
Mr. Joshua A. KazamCo-Founder & DirectorN/AN/A1977
Dr. Yasir B. Al-WakeelCFO & Head of Corp. Devel.N/AN/A1982
Ms. Barbara A. KosaczCOO & Gen. CounselN/AN/A1959
Dr. Christopher DinsmoreChief Scientific OfficerN/AN/A1967
Stephanie YaoExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Pasit Phiasivongsa Ph.D.Sr. VP of Pharmaceutical Devel.N/AN/AN/A
Mr. Charles Lin Ph.D.Sr. VP of BiologyN/AN/AN/A
Mr. David M. Tanen J.D.Sec. & DirectorN/AN/A1971
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Corporate Governance

Kronos Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.